Corporate ActionMay 5, 2026, 04:13 PM
Silexion Therapeutics Shareholders Approve 1-for-10 Reverse Split
AI Summary
Silexion Therapeutics Corp shareholders approved three key proposals at a reconvened extraordinary general meeting on May 5, 2026. The approved resolutions include an increase in the company's authorized share capital, an amendment to the 2024 Equity Incentive Plan to expand the share pool, and a 1-for-10 reverse share split. All proposals received affirmative votes from a simple majority of the shareholders present.
Key Highlights
- Shareholders approved increasing authorized share capital by 50,000,000 ordinary shares, from 9,000,000 to 59,000,000.
- The authorized share capital increased from $121,500 to $796,500.
- Shareholders approved amending the 2024 Equity Incentive Plan to increase the annual "evergreen" share pool to 10% of issued and outstanding shares.
- Shareholders approved a 1-for-10 reverse share split, consolidating shares and increasing par value from $0.0135 to $0.135.
- The Authorized Share Capital Increase Proposal passed with 61.4% of votes in favor.
- The Evergreen Increase Proposal passed with 61.4% of votes in favor.
- The Reverse Share Split Proposal passed with 61.3% of votes in favor.